B. Lathan

2.4k total citations · 1 hit paper
35 papers, 1.3k citations indexed

About

B. Lathan is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, B. Lathan has authored 35 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Hematology and 8 papers in Molecular Biology. Recurrent topics in B. Lathan's work include Acute Myeloid Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (8 papers) and Acute Lymphoblastic Leukemia research (7 papers). B. Lathan is often cited by papers focused on Acute Myeloid Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (8 papers) and Acute Lymphoblastic Leukemia research (7 papers). B. Lathan collaborates with scholars based in Germany, Switzerland and Austria. B. Lathan's co-authors include Volker Diehl, Hans Tesch, Michael Pfreundschuh, Dirk Hasenclever, Markus Loeffler, Jeremy Franklin, E. Dühmke, Hans–Konrad Müller–Hermelink, Richard Herrmann and Ursula Paulus and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

B. Lathan

34 papers receiving 1.3k citations

Hit Papers

Standard and Increased-Dose BEACOPP Chemotherapy Compared... 2003 2026 2010 2018 2003 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease
    2003 538 citations Volker Diehl, Jeremy Franklin et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B. Lathan Germany 14 750 646 339 270 250 35 1.3k
SJ Horning United States 18 1.0k 1.3× 884 1.4× 144 0.4× 173 0.6× 107 0.4× 39 1.7k
Maura Brugiatelli Italy 23 1.5k 2.0× 862 1.3× 261 0.8× 377 1.4× 146 0.6× 92 2.0k
Jens Ersbøll Denmark 15 449 0.6× 381 0.6× 188 0.6× 152 0.6× 209 0.8× 29 1.1k
Astrid Franke Germany 13 641 0.9× 403 0.6× 154 0.5× 143 0.5× 73 0.3× 28 1.0k
L Resegotti Italy 23 695 0.9× 624 1.0× 128 0.4× 186 0.7× 355 1.4× 93 1.8k
Franca Fossati Bellani Italy 18 245 0.3× 262 0.4× 343 1.0× 191 0.7× 242 1.0× 40 1.1k
Mars B. van ’t Veer Netherlands 15 536 0.7× 356 0.6× 198 0.6× 140 0.5× 262 1.0× 36 1.4k
Felicitas Hitz Switzerland 17 669 0.9× 560 0.9× 190 0.6× 195 0.7× 53 0.2× 63 1.1k
Nicole Straetmans Belgium 17 546 0.7× 572 0.9× 75 0.2× 97 0.4× 112 0.4× 44 1.1k
Burton J. Lee United States 15 568 0.8× 436 0.7× 237 0.7× 123 0.5× 60 0.2× 19 952

Countries citing papers authored by B. Lathan

Since Specialization
Citations

This map shows the geographic impact of B. Lathan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Lathan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Lathan more than expected).

Fields of papers citing papers by B. Lathan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Lathan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Lathan. The network helps show where B. Lathan may publish in the future.

Co-authorship network of co-authors of B. Lathan

This figure shows the co-authorship network connecting the top 25 collaborators of B. Lathan. A scholar is included among the top collaborators of B. Lathan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Lathan. B. Lathan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Diehl, Volker, Jeremy Franklin, Michael Pfreundschuh, et al.. (2003). Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease. New England Journal of Medicine. 348(24). 2386–2395. 538 indexed citations breakdown →
3.
Rüffer, Jens Ulrich, Hans‐Henning Flechtner, Andreas Josting, et al.. (2003). Fatigue in long-term survivors of Hodgkin‘s lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). European Journal of Cancer. 39(15). 2179–2186. 97 indexed citations
4.
Rueffer, U., Kai Breuer, Andreas Josting, et al.. (2001). Male gonadal dysfunction in patients with Hodgkin’s disease prior to treatment. Annals of Oncology. 12(9). 1307–1311. 131 indexed citations
5.
Staib, Peter, B. Lathan, Timo Schinköthe, et al.. (1999). Prognosis in Adult AML is Precisely Predicted by the Disc-Assay Using the Chemosensitivity-Index CI. Advances in experimental medicine and biology. 457. 437–444. 8 indexed citations
6.
Staib, Peter, B. Lathan, Hans Tesch, et al.. (1998). Cytosine arabinoside, etoposide and aclarubicin (AVA) for the treatment of acute myeloid leukemia (AML) in elderly patients. Annals of Oncology. 9(2). 221–223. 6 indexed citations
7.
Diehl, Volker, M. Sieber, B. Lathan, et al.. (1997). BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease. Annals of Oncology. 8(2). 143–148. 104 indexed citations
8.
Engert, Andreas, R. Schnell, Marcel Reiser, et al.. (1997). A Phase-II Study with Idarubicin, Ifosfamide and VP-16 (IIVP-16) in Patients with Refractory or Relapsed Aggressive and High Grade non-Hodgkin's Lymphoma. Leukemia & lymphoma. 24(5-6). 513–522. 13 indexed citations
9.
Pfreundschuh, Michael, U. Rueffer, B. Lathan, et al.. (1994). Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group.. Journal of Clinical Oncology. 12(3). 580–586. 95 indexed citations
10.
11.
12.
Musch, E., Jasna Peter‐Katalinić, Heinz Egge, et al.. (1992). Cellular kinetics of prednimustine versus chlorambucil plus prednisolone in vitro. Cancer Chemotherapy and Pharmacology. 29(4). 297–304. 1 indexed citations
13.
Büchner, Thomas, Wolfgang Hiddemann, U. W. Schaefer, et al.. (1992). Combined effect of very early intensification and prolonged post-remission chemotherapy in patients with AML.. PubMed. 6 Suppl 2. 68–70. 29 indexed citations
14.
Efferth, Thomas, B. Lathan, & M Volm. (1991). Selective growth-inhibition of multidrug-resistant CHO-cells by the monoclonal antibody 265/F4. British Journal of Cancer. 64(1). 87–89. 7 indexed citations
15.
Lathan, B., et al.. (1990). Pretherapeutic Drug Testing in Acute Leukemias for Prediction of Individual Prognosis. Hämatologie und Bluttransfusion. 33. 295–298. 11 indexed citations
16.
Lathan, B., Volker Diehl, Gary M. Clark, & Daniel D. Von Hoff. (1988). Cytotoxic activity of 9-β-d-arabinofuranosyl-2-fluoroadenine 5-monophosphate (fludarabine, NSC 312887) in a human tumor cloning system. European Journal of Cancer and Clinical Oncology. 24(12). 1891–1895. 12 indexed citations
17.
Volm, M, Thomas Efferth, Andreas Günther, & B. Lathan. (1987). Detection of murine S180 cells expressing a multidrug resistance phenotype using different in vitro test systems and a monoclonal antibody.. PubMed. 37(7). 862–7. 11 indexed citations
18.
Lathan, B., Gary M. Clark, & Daniel D. Von Hoff. (1985). In vitro comparison of vinzolidine and vinblastine: a model for methods of evaluation of analogues in a human tumor cloning system.. PubMed. 45(12 Pt 1). 6286–9. 3 indexed citations
19.
Lathan, B., et al.. (1984). Use of a human tumor cloning system to evaluate analogs of methotrexate and mitoxantrone.. PubMed. 68(5). 733–8. 23 indexed citations
20.
Lathan, B. & Daniel D. Von Hoff. (1984). Cytotoxic Activity of Echinomycin in a Human Tumor Cloning System. PubMed. 1(3). 191–198. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by SJ Horning Breakdown of academic impact, for papers by Maura Brugiatelli Breakdown of academic impact, for papers by Jens Ersbøll Breakdown of academic impact, for papers by Astrid Franke Breakdown of academic impact, for papers by L Resegotti Breakdown of academic impact, for papers by Franca Fossati Bellani Breakdown of academic impact, for papers by Mars B. van ’t Veer Breakdown of academic impact, for papers by Felicitas Hitz Breakdown of academic impact, for papers by Nicole Straetmans Breakdown of academic impact, for papers by Burton J. Lee
Rankless by CCL
2026